trending Market Intelligence /marketintelligence/en/news-insights/trending/ink3svt_ndjapesk0kedga2 content esgSubNav
In This List

Hikma appoints Teva unit head as CEO

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Hikma appoints Teva unit head as CEO

Hikma Pharmaceuticals PLC's board of directors appointed Sigurdur Olafsson as CEO with immediate effect.

Olafsson replaces Said Darwazah, Hikma's current chairman and CEO, who will assume the position of executive chairman of the company, the London-based drugmaker said in a news release.

Olafsson was most recently president and CEO of Teva Pharmaceutical Industries Ltd's global generic medicines group.